Prof. Farhad Ravandi – MRD in AML By Amnon Ron|2021-11-21T16:21:00+00:00November 21st, 2021|All|Comments Off on Prof. Farhad Ravandi – MRD in AML Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail About the Author: Amnon Ron Related Posts Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Prof. Florent Malard- The First microbiota therapy approved by the US FDA Prof. Florent Malard- The First microbiota therapy approved by the US FDA Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
